Cardiovascular Drugs Practice Questions

Q: Ranolazine is a?

Antianginal. **Explanation:** **Ranolazine** is a novel **antianginal** drug used primarily for the management of chronic stable angina. It is often used as a second-line agent or in combination with beta-blockers when symptoms are not adequately controlled. **Mechanism of Action:** The core mechanism involves the **selective inhibition of the late inward sodium current ($I_{Na}$)** in myocardial cells. During ischemia, there is an excess of late sodium entry, which leads to an intracellular calcium overload via the sodium-calcium exchanger. By blocking this sodium current, Ranolazine reduces calcium overload, improves myocardial relaxation (diastolic function), and decreases ventricular wall tension, thereby reducing oxygen demand **without** significantly affecting heart rate or blood pressure. **Analysis of Incorrect Options:** * **A. Vasodilator:** Unlike nitrates or calcium channel blockers, Ranolazine does not cause significant peripheral or coronary vasodilation. * **C. Antihypertensive:** Ranolazine has a negligible effect on systemic blood pressure and is not indicated for hypertension. * **D. Antiarrhythmic:** While it can prolong the QT interval (a property of Class III antiarrhythmics), it is not classified or clinically used as an antiarrhythmic agent. **High-Yield Clinical Pearls for NEET-PG:** * **Metabolism:** It is metabolized by **CYP3A4**; therefore, it is contraindicated with potent inhibitors like ketoconazole or clarithromycin. * **ECG Change:** It causes **QT interval prolongation**, but paradoxically, it carries a low risk of Torsades de Pointes. * **Metabolic Effect:** It can slightly reduce **HbA1c** levels, making it a favorable choice in diabetic patients with angina. * **Hemodynamics:** It is unique because it provides anti-ischemic benefits without decreasing heart rate or blood pressure (useful in patients with low baseline BP/HR).

Q: All of the following drugs act by blocking calcium channels except:

Dantrolene. **Explanation:** The core of this question lies in distinguishing between **Voltage-Gated Calcium Channels (VGCC)** found on cell membranes and **Ryanodine Receptors (RyR)** found on the sarcoplasmic reticulum. **1. Why Dantrolene is the correct answer:** Dantrolene does not block membrane calcium channels. Instead, it acts intracellularly by binding to the **Ryanodine Receptor (RyR1)** on the sarcoplasmic reticulum of skeletal muscle. This inhibits the release of calcium into the cytosol, thereby preventing muscle contraction. It is the drug of choice for **Malignant Hyperthermia** and **Neuroleptic Malignant Syndrome**. **2. Why the other options are incorrect:** * **Verapamil & Diltiazem:** These are Non-dihydropyridine Calcium Channel Blockers (CCBs). Verapamil (a Phenylalkylamine) acts primarily on the heart, while Diltiazem (a Benzothiazepine) acts on both the heart and blood vessels. They block **L-type voltage-gated calcium channels**. * **Nicardipine:** This is a Dihydropyridine (DHP) CCB. Like amlodipine and nifedipine, it selectively blocks L-type calcium channels in vascular smooth muscle, leading to vasodilation. **Clinical Pearls for NEET-PG:** * **Mnemonic for CCB classes:** **V**ery **D**iscrete **N**ature (**V**erapamil, **D**iltiazem, **N**ifedipine/Nicardipine). * **Dantrolene Side Effect:** Significant hepatotoxicity (monitor LFTs). * **Drug of Choice:** Verapamil is the DOC for prophylaxis of Cluster Headaches and Paroxysmal Supraventricular Tachycardia (PSVT). * **Nimodipine:** A specific CCB used to prevent vasospasm in Subarachnoid Hemorrhage (SAH).

Q: Which of the following antiarrhythmic drugs has the most prominent anticholinergic action?

Disopyramide. **Explanation:** **Disopyramide** is a Class IA antiarrhythmic drug known for its potent **anticholinergic (atropine-like) effects**. Among all antiarrhythmic agents, it possesses the most significant muscarinic receptor-blocking activity. This leads to classic side effects such as dry mouth, blurred vision, urinary retention (especially in elderly males with BPH), and constipation. Clinically, its vagolytic action can paradoxically increase the heart rate by enhancing AV nodal conduction, which is why it is often co-administered with AV nodal blockers. **Analysis of Other Options:** * **Quinidine (Option A):** While Quinidine also possesses anticholinergic properties, they are significantly **less potent** than those of Disopyramide. Quinidine is more famously associated with "Cinchonism" (tinnitus, headache, dizziness) and alpha-blocking activity (causing hypotension). * **Lignocaine (Option B):** A Class IB agent that works primarily on inactivated sodium channels in ischemic tissues. It has **no anticholinergic activity** and is mainly associated with CNS side effects (seizures, tremors). * **Procainamide (Option C):** A Class IA agent with the **least anticholinergic effect** in its class. Its primary clinical concern is the development of a Reversible Lupus-like syndrome (in slow acetylators). **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Disopyramide is uniquely used in **Hypertrophic Obstructive Cardiomyopathy (HOCM)** because its negative inotropic effect helps reduce the outflow gradient. * **Contraindication:** Due to its strong anticholinergic profile, it is strictly contraindicated in patients with **Glaucoma** and **Prostatic Hypertrophy**. * **Class IA Mnemonic:** "**P**olice **D**epartment **Q**uarter" (**P**rocainamide, **D**isopyramide, **Q**uinidine). All Class IA drugs increase the APD and QT interval.

Q: Amrinone acts by?

Inhibiting phosphodiesterase. **Explanation:** **Amrinone** (and its derivative Milrinone) belongs to the class of **Bipyridines**. These drugs act as selective **Phosphodiesterase-3 (PDE-3) inhibitors**. 1. **Mechanism of Action (Why A is correct):** In cardiac myocytes, PDE-3 is responsible for the degradation of cyclic AMP (cAMP). By inhibiting this enzyme, Amrinone increases intracellular cAMP levels. This leads to increased calcium influx during action potentials, resulting in a **positive inotropic effect** (increased contractility). In vascular smooth muscle, the rise in cAMP causes relaxation, leading to **vasodilation** (decreased preload and afterload). Due to this dual action, these drugs are often called **"Inodilators."** 2. **Analysis of Incorrect Options:** * **B. ATPase inhibitor:** This describes **Digoxin** (Cardiac glycosides), which inhibits the Na+/K+-ATPase pump. * **C. Calcium channel blocker:** Drugs like Verapamil or Diltiazem block L-type calcium channels, leading to negative inotropy and vasodilation (the opposite of Amrinone’s cardiac effect). * **D. K+ channel opener:** Drugs like Minoxidil or Nicorandil open potassium channels, primarily causing hyperpolarization and vasodilation, but they do not have direct positive inotropic effects. **High-Yield Clinical Pearls for NEET-PG:** * **Indication:** Short-term management of severe acute heart failure or refractory chronic heart failure. * **Side Effects:** A major limiting side effect of **Amrinone is Thrombocytopenia** (less common with Milrinone). * **Milrinone** is generally preferred over Amrinone due to its higher potency, shorter half-life, and lower risk of bone marrow suppression. * **Note:** Long-term oral use of PDE-3 inhibitors is avoided as it has been shown to increase mortality in heart failure patients.

Q: Which of the following is NOT a side effect of Nimodipine?

Marked changes in GIT motility. **Explanation:** **Nimodipine** is a second-generation dihydropyridine (DHP) calcium channel blocker (CCB). Its primary mechanism involves blocking L-type calcium channels, leading to smooth muscle relaxation. **Why "Marked changes in GIT motility" is the correct answer:** While non-dihydropyridines like Verapamil are notorious for causing significant constipation (due to inhibition of calcium-dependent contractions in the colonic muscularis), **dihydropyridines like Nimodipine have minimal effect on gastrointestinal motility.** Nimodipine is highly lipid-soluble and possesses a unique cerebrovascular selectivity, making it the drug of choice for preventing vasospasm following **Subarachnoid Hemorrhage (SAH)**. **Analysis of Incorrect Options:** * **A. Hypotension:** Like all DHPs, Nimodipine causes peripheral vasodilation. Although it is more selective for cerebral vessels, systemic vasodilation can still occur, leading to a drop in blood pressure. * **B. Flushing:** This is a common side effect of the DHP class resulting from cutaneous vasodilation. * **C. Headache:** Vasodilation of meningeal vessels is a frequent side effect of CCBs, often presenting as a throbbing headache. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Nimodipine is the standard of care to improve neurological outcomes in patients with **Aneurysmal Subarachnoid Hemorrhage**. * **Selectivity:** It is highly lipophilic, allowing it to cross the blood-brain barrier effectively. * **Verapamil vs. DHPs:** Remember that **Verapamil** is the CCB most commonly associated with **constipation** (GIT motility changes). * **DHP Side Effect Profile:** Think of the "Vasodilatory Triad": Headache, Flushing, and Ankle Edema.

Q: Which of the following antiarrhythmic drugs can decrease the slope of Phase 0 and prolong the action potential duration?

Quinidine. **Explanation:** The question describes the characteristic electrophysiological profile of **Class IA antiarrhythmics**. **1. Why Quinidine is Correct:** Quinidine belongs to **Vaughan Williams Class IA**. Its mechanism involves: * **Sodium Channel Blockade (Phase 0):** By blocking fast inward $Na^+$ channels, it decreases the rate of depolarization (slope of Phase 0). * **Potassium Channel Blockade (Phase 3):** It inhibits outward $K^+$ currents, which delays repolarization, thereby **prolonging the Action Potential Duration (APD)** and the Effective Refractory Period (ERP). **2. Why the other options are incorrect:** * **Lignocaine (Class IB):** While it blocks $Na^+$ channels, it typically **shortens** or has no effect on the APD. It preferentially binds to channels in the inactivated state (common in ischemic tissue). * **Propranolol (Class II):** A Beta-blocker that acts primarily by decreasing the slope of **Phase 4** (pacemaker potential) in the SA node. It does not significantly affect Phase 0 of the ventricular action potential. * **Adenosine:** Acts via $A_1$ receptors to increase $K^+$ conductance and decrease $Ca^{2+}$ current in the AV node. It causes hyperpolarization and is used for terminating PSVT, not for modifying ventricular APD in this manner. **High-Yield NEET-PG Pearls:** * **Class IA Mnemonic:** "**P**yramid **Q**ueen **D**isappears" (**P**rocainamide, **Q**uinidine, **D**isopyramide). All three increase APD and QT interval. * **Side Effect:** Quinidine can cause **Cinchonism** (tinnitus, vertigo) and **Torsades de Pointes** due to QT prolongation. * **Drug Interaction:** Quinidine increases plasma levels of **Digoxin** by displacing it from tissue binding sites and reducing renal clearance.

Q: Which hypolipidemic drug acts primarily by decreasing VLDL?

Fibrates. **Explanation:** **Fibrates (e.g., Fenofibrate, Gemfibrozil)** are the correct answer because their primary mechanism of action is the activation of **Peroxisome Proliferator-Activated Receptor-alpha (PPAR-α)**. This leads to an increase in the synthesis of Lipoprotein Lipase (LPL), which enhances the clearance of triglyceride-rich lipoproteins. Consequently, fibrates significantly decrease the production and increase the catabolism of **VLDL** (Very Low-Density Lipoprotein), making them the drugs of choice for severe hypertriglyceridemia. **Analysis of Incorrect Options:** * **Nicotinic Acid (Niacin):** While it reduces VLDL and LDL, its most distinctive clinical effect is being the most potent agent for **increasing HDL** levels. It acts by inhibiting adipose tissue lipolysis. * **Statins (HMG-CoA Reductase Inhibitors):** These are the first-line drugs for hypercholesterolemia. Their primary action is decreasing **LDL** by inhibiting cholesterol synthesis and upregulating LDL receptors. * **Cholestyramine (Bile Acid Sequestrants):** These act locally in the intestine to prevent bile acid reabsorption. This forces the liver to use more cholesterol to synthesize new bile acids, primarily resulting in a decrease in **LDL**. **NEET-PG High-Yield Pearls:** * **Drug of choice for Hypertriglyceridemia:** Fibrates. * **Drug of choice for Hypercholesterolemia:** Statins. * **Side Effect Alert:** Combining Statins and Fibrates (especially Gemfibrozil) significantly increases the risk of **myopathy and rhabdomyolysis** due to competition for glucuronidation pathways. * **Fenofibrate** is the preferred fibrate to use with statins as it has a lower risk of causing myopathy.

Q: Digitalis acts in Congestive Heart Failure by which mechanism?

Na+/K+ ATPase inhibition. **Explanation:** **Mechanism of Action (Correct Option A):** Digitalis (Digoxin) acts by reversibly inhibiting the **Na+/K+ ATPase pump** located on the sarcolemma of cardiac myocytes [1]. This inhibition leads to an accumulation of intracellular sodium ($Na^+$). The increased intracellular $Na^+$ reduces the concentration gradient that drives the **Na+/Ca2+ exchanger (NCX)** [2]. Consequently, the extrusion of calcium ($Ca^{2+}$) from the cell is decreased, leading to higher intracellular $Ca^{2+}$ levels [2]. This excess calcium is sequestered into the Sarcoplasmic Reticulum, resulting in increased calcium release during subsequent depolarizations, which enhances myocardial contractility (**Positive Inotropic Effect**) [1]. **Analysis of Incorrect Options:** * **B. Na+/K+ ATPase stimulation:** This would decrease intracellular sodium and calcium, leading to a negative inotropic effect, which is the opposite of the desired therapeutic goal in heart failure. * **C. Blockade of calcium channels:** Calcium channel blockers (like Verapamil) decrease contractility (negative inotropy) and are generally avoided in systolic heart failure. * **D. Increasing the refractory period of the AV node:** While Digoxin *does* do this via vagomimetic action, this is its mechanism for controlling rate in **Atrial Fibrillation**, not its primary mechanism for improving cardiac output in **Congestive Heart Failure** [1]. **High-Yield Clinical Pearls for NEET-PG:** * **Electrolyte sensitivity:** Hypokalemia, hypomagnesemia, and hypercalcemia predispose to Digoxin toxicity [1]. * **ECG Changes:** The earliest sign of toxicity is often PVCs; the most characteristic sign is the "reverse tick" or "sagging" ST-segment depression. * **Drug of Choice:** Digoxin is the drug of choice for Heart Failure with concomitant Atrial Fibrillation. * **Antidote:** Digibind (Digoxin-specific Fab fragments).

Question 1

Nitrates are not indicated in which of the following conditions?

Accepted Answer

Renal colic

Answer

Congestive heart failure

Answer

Cyanide poisoning

Answer

Esophageal spasm

Question 2

Sublingual nitroglycerin for the treatment of acute chest pain can cause which of the following?

Accepted Answer

Headache

Answer

Hypotension

Answer

Bradycardia

Answer

Sexual dysfunction

Question 3

Ranolazine is a?

Accepted Answer

Antianginal

Answer

Vasodilator

Answer

Antihypertensive

Answer

Antiarrhythmic

Question 4

All of the following drugs act by blocking calcium channels except:

Accepted Answer

Dantrolene

Answer

Nicardipine

Answer

Diltiazem

Answer

Verapamil

Question 5

Which of the following antiarrhythmic drugs has the most prominent anticholinergic action?

Accepted Answer

Disopyramide

Answer

Quinidine

Answer

Lignocaine

Answer

Procainamide

Question 6

Amrinone acts by?

Accepted Answer

Inhibiting phosphodiesterase

Answer

ATPase inhibitor

Answer

Calcium channel blocker

Answer

IC/ channel opener

Question 7

Which of the following is NOT a side effect of Nimodipine?

Accepted Answer

Marked changes in GIT motility

Answer

Hypotension

Answer

Flushing

Answer

Headache

Question 8

Which of the following antiarrhythmic drugs can decrease the slope of Phase 0 and prolong the action potential duration?

Accepted Answer

Quinidine

Answer

Lignocaine

Answer

Propranolol

Answer

Adenosine

Question 9

Which hypolipidemic drug acts primarily by decreasing VLDL?

Accepted Answer

Fibrates

Answer

Nicotinic acid

Answer

Statins

Answer

Cholestyramine

Question 10

Digitalis acts in Congestive Heart Failure by which mechanism?

Accepted Answer

Na+/K+ ATPase inhibition

Answer

Na+/K+ ATPase stimulation

Answer

Blockade of calcium channels

Answer

Increasing the refractory period of the AV node

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?